Dyne announces additional one-year data from ACHIEVE study

Dyne Therapeutics (DYN) last night announced additional one-year data from its ongoing Phase 1/2 ACHIEVE clinical trial of zeleciment basivarsen in patients with myotonic dystrophy type 1. The one-year data presented at Congress of the World Muscle Society come from adults with DM1 enrolled in the cohort assessing the selected registrational dose of 6.8 mg/kg in the randomized, placebo-controlled multiple ascending dose portion of the ACHIEVE trial. Dyne highlights “robust and sustained improvement from baseline in hand myotonia, as measured by video hand opening time” and “meaningful and sustained improvements from baseline in multiple functional endpoints, including data from the 10-Meter Walk/Run Test and the 5 Times Sit to Stand Test.” New data show improvement in the 9-Hole Peg Test, a measure of upper limb function focused on manual dexterity and coordination, which is frequently used across neurological conditions, the company added. Shares of Dyne are up 4% to $13.20 in premarket trading.